Cantor Fitzgerald Initiates Coverage On Ovid Therapeutics with Overweight Rating
Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Overweight rating.
Share
Why It Matters
A big investment bank's analyst just started following Ovid Therapeutics and gave it a thumbs up. When smart analysts like this company, it shows they think good things might happen.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.